Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency	Synageva	Completed	Sebelipase alfa (SBC-102)	2	LAL-CL03	KFSH & RC-R
"An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure "	AstraZeneca	Completed	Dapagliflozin	3	D169CC00001	KKUH
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care	GDRS (MOH)	Ongoing	Hydroxychloroquine sulphate	3	version 8	QCH
"ALL SCTped 2012 FORUM Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia"	KAIMRC	Ongoing	BUSULFAN	3	CT17/016/R	NGHA-R
Adjunct Low Dose Ketamine Infusion Versus Standard of Care in Mechanically Ventilated Critically Ill Patients at a Tertiary Saudi Hospital (ATTAINMENT Trial): Randomized, Prospective, Pilot Trial	King Faisal Specialist Hospital and Research Centre	Ongoing	Ketamine	3	2191187	KFSH & RC-R
A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy.	Roche	Ongoing	RO7034067	2	BP39056	KFSH&RC-R
A Trial of Favipiravir in Adults with Mild Coronavirus Disease Covid-19	KAIMRC	Ongoing	Favipiravir	3	RC20/220/R	NGHA-R
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19	KAIMRC	Terminated	Favipiravir	3	RC20/174/R	NGHA-R
A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole.	Novartis	Rejected	Everolimus + Exemestane VS. Everolimus VS. Capecitabine	2	CRAD001Y2201	KFSH & RC-R
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy	Novartis	Ongoing	Ofatumumab	3b	COMB157G23101	King Faisal Specialist Hospital and Research Center (Jeddah)